 curcumin, compounds 3a, 3b and 3e and IC 50 was 17.41, 17.11, 14.02 and 18.7 
I. Introduction
Cardiovascular disease (CVD) is a major cause of the human death in India and in many countries. Hyperlipidemia is a common threat for the accelerated atherosclerosis and cardiovascular diseases. Atherosclerosis is characterized by the formation of plaques in the walls of coronary arteries that reduces the flow of blood leading to coronary artery disease. Hypercholesterolemia contributes to the increased prevalence of coronary artery diseases [1] . Previous reports show that lowering of serum cholesterol reduces the risk of coronary artery diseases [2] .
Many plants have been recognized as hypolipidemic in ayurveda, an Indian traditional medicine [3] . Curcumin is a polyphenol and is the chief active component of rhizome of the plant Curcuma longa, commonly called as turmeric. Turmeric, a traditional medicinal plant forms a vital class of adjuncts in our diet. A wide-ranging research over the decades on this polyphenol indicated that it is a persuasive therapeutic agent against various diseases [4] . Curcumin has been found to be safe even at very high doses in human clinical trials [5] . Though curcumin is used for various treatments owing to its medicinal properties, it is not an effective therapeutic molecule due to its bioavailability [6] . Numerous approaches are being sought to trounce these limitations. A variety of chemical modifications of curcumin have been studied and different analogues were synthesized to advance its pharmacological effects [7] [8] [9] . In our preceding study, we had synthesized ethanone pyridine curcumin analogues and cyclopropoxy curcumin analogues. These compounds showed anti angiogenic and in-vivo growth inhibitory effects against mouse tumor [10, 11] . Further, curcumin pyrazole (3a-3e) series were synthesized ( Fig.1) and checked for its bioavailability [12] . The derivatives of the curcumin pyrazole series (3a-3e) were demonstrated antiproliferate, antioxidant and antidiabetic properties [12] [13] [14] .
Extending the evaluation of biological activities of curcumin pyrazole series (3a-3e), in the present study, we investigated for the in-vitro hypolipidemic potential of the curcumin and its pyrazole derivatives by assessing the inhibition of the malic dehydrogenase, pancreatic lipase and glucose 6 phosphate dehydrogenase enzymes.
II. Materials and Methods

Materials
All solvents and other chemicals used in the studies were of analytical grade and purchased from SDFCL, Mumbai, India. The enzyme, NADP-malic enzyme (EC 1.1.1.40) was obtained from Sigma Aldrich, Bengaluru. The other enzymes glucose 6 phosphate dehydrogenase (EC 1.1.1.49) and pancreatic lipase (EC 3.1.1.3) were purchased from SRL, India.
Methods 2.2.1 Inhibition of pancreatic lipase activity
Hypolipidemic ability of curcumin and the pyrazole derivatives (3a-3e) were tested by assessing the pancreatic lipase inhibition assay [15] . Curcumin and its pyrazole derivatives (3a-3e) were individually DOI: 10.9790/3008-1104030408 www.iosrjournals.org 5 | Page incubated with 1ml of reaction mixture containing 1Unit of lipase enzyme, 100mM phosphate buffer (pH 7.2) with triton-X-100 (0.5%). The enzyme reaction was started by adding p-nitro phenyl butyrate (5mM in acetonitrile) and monitored at 340nm. A control tube was maintained and the result was expressed as percent activity.
Inhibition of glucose-6-phosphate dehydrogenase activity
Glucose-6-phosphate dehydrogenase activity was measured by monitoring reduction of NADP at 340nm [16] . Curcumin and its pyrazole derivatives (3a-3e) were individually incubated with 1ml of reaction mixture containing 0.5 Unit of enzyme, 50mM Tris HCl (pH 7.4) and 0.1mM Glucose-6-phosphate. The enzyme reaction was started by adding 0.15 mM NADP and monitored at 340nm. A control tube was maintained and the result was expressed as percent activity.
Inhibition of malic dehydrogenase activity
Malic dehydrogenase activity was measured by monitoring reduction of NADP at 340nm [17] . Curcumin and its pyrazole derivatives (3a-3e) were incubated with 1ml of Tris HCl (100mM, pH 7.4) containing 0.5 Unit of Malic dehydrogenase enzyme, L-malate (10mM) and MnCl 2 (2mM). The enzyme reaction was started by adding 2mM NADP and monitored at 340nm. A control tube was maintained and the result was expressed as percent activity.
Statistical analysis
The data obtained were analyzed using MS-excel software. The data were expressed as mean±standard error of mean and all the experiments were compared with control and performed in triplicates.
III. Results and Discussion
Pancreatic lipase enzyme inhibition assay
The enzyme inhibitory efficiency of curcumin and its pyrazole derivatives (3a-3e) on pancreatic lipase at different concentrations (20-80 µM) was depicted (Fig. 2) .
The activity of the pancreatic lipase enzyme in the compound 3b treated tubes was found to be 37.5±0.31, 35±0.15 and 27.5±0.21% at the concentrations of 20, 40 and 80 µM respectively. The decrease in the activity of enzyme in the curcumin treated tubes was also predominant and the activity was found to be 42.5±0.11, 37.5±0.23 and 30±0.19% at 20, 40 and 80 µM respectively. The activity of enzyme was found to be 35±0.16% in the tube treated with 80 µM concentration of compound 3e. The other compounds in the series showed the moderate enzyme inhibitory activity. Compounds 3a, 3c and 3d decreased the percent activity of pancreatic lipase and the activity was found to be 47.5±0.32, 52.5±0.41 and 57.5±0.36 respectively at 80 µM concentration.
CVD is characterized by increased activity of lipases specifically, pancreatic lipases which catalyze the breakdown reactions of dietary fat into simpler fatty acids which are absorbed into the system. The enzyme activity usually increases with diabetes and CVD causing an increased absorption of fatty acids from dietary fat [15, 19] that increases free saturated fatty acids. When the enzyme pancreatic lipase was treated with the curcumin and its derivatives (3a-3e) the activity was decreased significantly in the tubes treated with curcumin, compound 3b and 3e when compared to the other compounds in the series. The IC 50 for curcumin and compound 3b was prominent and was found to be 17.39 µM and 16 µM respectively (Table-1). Compound 3b was found to be more effective than the curcumin. Our previous reports suggested that compound 3b possess potent biological activities when compared with the others in the series. The potential biological activities of compound 3b may be attributed to the structure activity relationship which needs further investigation.
Malic dehydrogenase enzyme inhibition assay
The malic dehydrogenase enzyme inhibitory effect of curcumin and its pyrazole derivatives (3a-3e) at different concentrations (20-80 µM) was studied and the results are shown in the Fig. 3 . The activity of enzyme in the curcumin treated tubes was found to be 57.3±0.24, 38.2±0.21 and 26.96±0.35% at 20, 40 and 80 µM respectively and in compound 3a treated tubes, it was found to be 46.06±0.32, 33.7±0.27 and 31.46±0.25% at the concentrations of 20, 40 and 80 µM respectively. The activity of enzyme in the compound 3b treated tubes was found to be 56.17±0.29, 34.83±0.22 and 26.96±0.19% at the concentrations of 20, 40 and 80 µM respectively. The other compounds in the series also showed moderate enzyme inhibitory activity. It was found to be 41.57±0.34, 46.06±0.29 and 37.07±0.18% in compounds 3c, 3d and 3e treated tubes respectively at 80 µM concentration.
NADP-malic enzyme has shown to be an important enzyme in regulating the extent of lipid accumulation in a filamentous fungus (20) . The activity of the enzyme was decreased significantly in the tubes Tables   Fig 1. Series of curcumin pyrazole derivatives (3a-3e) 
IV. Figures and
V. Conclusion
Curcumin and its pyrazole derivatives (3a-3e) were studied to estimate the hypoglycemic effects of the compounds by the inhibition assays of the enzymes pancreatic lipase, glucose 6 phosphate dehydrogenase and malate dehydrogenase. All the compounds assessed exhibited hypolipidemic activity by attenuating the activity of the enzymes studied. Compound 3a and 3b was found to possess a prominent inhibitory activity which was comparable with the inhibitory activity of the curcumin. Compound 3b was found to be more potent enzyme inhibitor. From our present investigations, compound 3a and compound 3b could be concluded as promising hypolipidemic agents. However, further studies are needed to analyze structure activity interactions responsible for the overall hypolipidemic activities.
